<DOC>
	<DOCNO>NCT01718041</DOCNO>
	<brief_summary>This Phase 1b/2a study VRS-317 ( long-acting growth hormone ) pediatric patient growth hormone deficiency . During Phase 1b , pediatric patient receive single subcutaneous injection VRS-317 . During Phase 2a stage , patient receive 6 month VRS-317 treatment dose level select Phase 1b stage . The primary endpoint study determine safety efficacy repeat dose VRS-317 .</brief_summary>
	<brief_title>Versartis Trial Children Assess Long-Acting Growth Hormone</brief_title>
	<detailed_description>In Phase 1b , separate cohort patient test single ascend dose format . Safety review committee meeting take place prior escalate increase dose level . Enrolled patient monitor 60 day safety PK/PD safety lab collect . Two dose level select completion Phase 1b test Phase 2a ( 6 month continuous VRS-317 treatment ) . Safety PK assessment make Phase 2a stage . Patient height measure stadiometer .</detailed_description>
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Chronological Age ≥ 3.0 year ≤ 11.0 Diagnosis GHD document GH stimulation test Below average height SDS screen Appropriate weight Stature Decreased IGFI SDS screen Delayed bone age Normal thyroid function test result screen visit Legally authorize representative inform consent . Prior treatment growth promote agent Documented history , current , significant disease Chromosomal aneuploidy , significant gene mutation Diagnosis Attention Deficit Hyperactivity Disorder Daily use antiinflammatory dos glucocorticoid Prior history leukemia , lymphoma , sarcoma cancer Known allergy constituent study drug formulation Abnormal ocular finding screen Significant abnormality screen laboratory study</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Growth hormone</keyword>
	<keyword>Growth hormone deficiency</keyword>
	<keyword>Growth</keyword>
	<keyword>Pediatric growth hormone deficiency</keyword>
	<keyword>Long act growth hormone</keyword>
	<keyword>GHD</keyword>
	<keyword>PGHD</keyword>
	<keyword>VRS 317</keyword>
	<keyword>Exten</keyword>
	<keyword>Versartis</keyword>
</DOC>